Organic Active Ingredients TRIZ Cases

A mucoadhesive buccal film delivers non-nanoparticulate macrolides via direct mucosal absorption.

Segmenting the pathway via specific NIK targeting resolves selectivity trade-offs, reducing off-target effects while preserving immune function.

Antisense oligonucleotides inhibit BRCA2 and RAD51 expression, inducing synthetic lethality to overcome chemoresistance.

6-Azaindazole compounds antagonize Wnt pathway activity, correcting aberrant growth states in cancer and genetic disorders.

Ethanol-water precipitation yields stable Ortataxel polymorphs, eliminating volatile acetone impurities that violate ICH guidelines.

A multiple emulsion uses Poloxamer 407 and triacylglycerides to encapsulate active ingredients within a stable water-in-oil-in-water structure.

Segmented therapeutic agents target unaddressed ErbB3 pathways, blocking phosphorylation and tumor growth without modifying intracellular domains.

Novel compounds selectively bind to chemokine receptor 2, reducing macrophage-induced inflammation while minimizing off-target effects on receptor 5.

Macrocyclic compounds inhibit serine protease coagulation factor VIIa through rigid structural frameworks.

Continuous countercurrent leaching and xylanase enzymolysis produce soluble dietary fiber with high xylooligosaccharide purity.

An aldehyde-functionalized polymer shields acid-sensitive proteins from denaturation, enabling rapid gelling and strong adhesion in surgical applications.

Nucleoside agents inhibit toxic RNA production from mutant extended nucleotide repeat genes.

Liquid flavor mixture impregnates chewing gum core prior to coating, resolving processability issues from softening.

Acidified polymeric matrices sustain melatonin release over 2 to 10 hours, resolving low bioavailability caused by gastrointestinal pH variations.

Targeting lncRNAs like Gm11641 resolves the trade-off between therapeutic versatility and effectiveness by modulating intracellular signaling pathways.

A herbal powder formulation uses inulin and natural extracts to enhance immunity without added excipients.

Developing stable crystalline forms and solvates resolves unpredictability in polymorphism, ensuring reliable bioavailability.

Canagliflozin monohydrate crystalline forms resist phase transformation in water, ensuring reliable pharmaceutical dosing accuracy.

PAK-1 inhibitors interrupt the Rac2 signaling axis to resolve excessive inflammatory responses.

Fatty acid ester mediates DMAE solubility in acrylic adhesive, improving preservation stability and transdermal absorbency.

Segmented quinoline derivatives with optimized substituents inhibit Bruton's tyrosine kinase to treat B cell malignancies.

Shortened double-stranded regions in asymmetric RNAi compounds enable nuclear penetration, resolving the trade-off between rigid structure and cellular uptake.

Combines short-acting hypnotics with long-acting agents to enhance slow-wave sleep while avoiding next-day dysfunction.

Controlled crystallization transforms amorphous C-Met inhibitors into stable crystal forms, resolving low solubility and chemical instability.

Charge masking agents disaggregate lens proteins to inhibit cataract progression without surgical intervention.

Specific amino acids reduce oxidized coenzyme Q10 while preventing oxidation, eliminating hazardous agent removal and flavor degradation.

siRNA inhibitors reduce GST-π expression in cancer cells, shrinking malignant tumors without inducing unwanted autophagy.

Combining MDM2 inhibitors with immune checkpoint modulators increases cytotoxic T cell concentration in the tumor microenvironment.

Polycaprolactone gel formulations overcome manufacturing complexity and high costs associated with micellar compositions by enhancing skin penetration.

Layered seal and release coatings on micronized Clozapine pellets prevent humidity degradation, maintaining less than 2% total impurities after six months.

A pharmaceutical capsule composition comprising fingolimod hydrochloride and specific excipients achieves stable content uniformity.

Granulated pimavanserin capsules resolve large tablet size issues by improving bulk density and flowability for patient compliance.

Broken-up algae compositions degrade hydrogen peroxide via catalase activity to address wrinkles, thinning, and brittleness without irritation.

Amide compounds modulate the glucagon receptor to reduce glycemic levels while minimizing side effects associated with existing antagonists.

Pyrazolone derivatives donate nitroxyl via chemical decomposition, resolving solid state stability and bioavailability trade-offs.

A lipid nanoparticle membrane composition combines cationic lipids, cholesterol, and dual PEG chains to enhance particle stability.

A pharmaceutical compound induces apoptosis in myeloma cells while sparing normal bone marrow tissue.

Modulating the PD-1 pathway with microRNAs addresses ineffective IPF treatments by slowing disease progression.

Targeting the IL-6 receptor pathway resolves persistent non-inflammatory pain after inflammation control.

Deuterated Hedgehog inhibitors lower Gli1 and PTCH expression to treat basal cell carcinoma.

A pharmaceutical composition forms a protective mucin layer on the gastric mucosa using hyaluronic acid and plant extracts.

Combining pyridostigmine with a 5-HT3 receptor antagonist enables safe administration of fully effective doses.

2-(1H-indolylsulfanyl)-aryl amine derivatives inhibit serotonin, norepinephrine, and dopamine reuptake simultaneously.

New crystalline forms of Encequidar mesylate enhance chemical stability and bioavailability for pharmaceutical formulations.

Antioxidants in carbidopa formulations prevent hydrazine generation from degradation, ensuring continuous dopaminergic stimulation.

A solid preparation uses a porous excipient to coat a self-emulsifying dutasteride composition.